| Literature DB >> 33921585 |
Mikolaj Przydacz1, Michal Skalski2, Jerzy Sobanski3, Marcin Chlosta1, Karol Raczynski1, Katarzyna Klasa3, Dominika Dudek4, Piotr Chlosta1.
Abstract
Background andEntities:
Keywords: depression; lower urinary tract symptoms; sleep
Mesh:
Year: 2021 PMID: 33921585 PMCID: PMC8073100 DOI: 10.3390/medicina57040394
Source DB: PubMed Journal: Medicina (Kaunas) ISSN: 1010-660X Impact factor: 2.430
Demographics of included patients.
| Specification | Total, N (%) |
|---|---|
| Number of included patients | 102 (100%) |
| Sex | |
| Male | 42 |
| Female | 60 |
| Education | |
| Primary | 3 |
| Secondary (including students) | 45 |
| Higher | 54 |
| Employment status | |
| Employed | 55 |
| Unemployed | 13 |
| Pensioners | 30 |
| Students | 4 |
| Relationship | |
| Stable relationship/marriage | 73 |
| Unstable relationship/marriage | 12 |
| Single | 17 |
Drugs taken by the included patients. SNRIs—serotonin norepinephrine reuptake inhibitors; SSRIs—selective serotonin reuptake inhibitors; TCAs—tricyclic antidepressants; NaSSAs—noradrenergic and specific serotonergic antidepressants; SARIs—serotonin antagonist and reuptake inhibitors.
| Drugs | Number of Patients |
|---|---|
| Antidepressants | |
| SNRIs | 47 |
| SSRIs | 46 |
| TCAs | 23 |
| NaSSAs | 21 |
| SARIs | 21 |
| Lithium | 14 |
| Others antidepressants | 10 |
| Anti-epileptics | |
| Valproate | 23 |
| Lamotrigine | 16 |
| Carbamazepine | 10 |
| Neuroleptics, first generation | |
| Phenothiazines | 35 |
| Thioxanthenes | 13 |
| Butyrophenones | 6 |
| Neuroleptics, second generation | |
| Quetiapine | 24 |
| Sulpiride | 16 |
| Olanzapine | 14 |
| Aripiprazole | 8 |
| Other neuroleptics | 6 |
| Anxiolytics | |
| Benzodiazepines | 33 |
| Hydroxyzine | 10 |
| Buspirone | 3 |
Of note: Other antidepressants—tianeptine, norepinephrine and dopamine reuptake inhibitors (NDRIs), norepinephrine reuptake inhibitors (NRIs), reversible monoamine oxidase inhibitor (RIMAs), agomelatine. Other neuroleptics—risperidone, clozapine, amisulpride.
Figure 1Correlations of depression severity based on HRSD (score in categories) and sleep quality based on HSDQ in the study groups. (A) All, (B) women, (C) men.
Figure 2Comparison of depressed patients with mild or no urological symptoms (Group A, n = 70) and depressed patients with moderate or severe urological symptoms (Group B, n = 32) in terms of the sleep quality based on HSDQ.
Comparative characteristic of depressed patients with mild or no urological symptoms (Group A, n = 70) and depressed patients with moderate or severe urological symptoms (Group B, n = 32) in terms of the sleep quality based on HSDQ.
| Group A | Group B | ||
|---|---|---|---|
| HSDQ | 0.0450 1 | ||
| Mean (standard deviation) | 69.4 (17.4) | 82.5 (22.4) | |
| Range | 34.0–91.0 | 38.0–134.0 | |
| Median | 72.0 | 81.5 | |
| 95% confidence interval | [59.3;79.4] | [77.1;87.8] |
1 U Mann–Whitney.
Regression analysis of the effect of depression severity, lower urinary tract symptoms (LUTS) assessed with IPSS, and urinary incontinence (UI) assessed with the ICIQ-SF UI on sleep quality in patients with depression regardless of age and sex.
| Parameter | |
|---|---|
| HRSD |
|
| Remission/no depression (0–7) |
|
| Mild depression (8–16) | 0.2123 |
| Moderate depression (17–23) | 0.2780 |
| Severe depression (≥24) |
|
| HRSD (0–16) |
|
| HRSD (≥17) |
|
| IPSS |
|
| None (0) |
|
| Mild LUTS (1–7) | 0.1659 |
| Moderate LUTS (8–19) | 0.1306 |
| Severe LUTS (20–35) |
|
| ICIQ-UI SF |
|
| Mild UI (1–5) |
|
| Moderate UI (6–12) | 0.1030 |
| Severe UI (13–18) |
|
| Very severe UI (19–21) | 0.2865 |
The bold figures indicate statistically significant results.